Study of the anticancer properties of optically active titanocene oximato compounds by de la Cueva-Alique, I. et al.
Accepted Manuscript
Study of the anticancer properties of optically active titanocene oximato compounds
Isabel de la Cueva-Alique, Sara Sierra, Adrián Pérez-Redondo, Isabel Marzo,
Lourdes Gude, Tomás Cuenc, Eva Royo
PII: S0022-328X(18)31021-0
DOI: https://doi.org/10.1016/j.jorganchem.2018.12.011
Reference: JOM 20668
To appear in: Journal of Organometallic Chemistry
Received Date: 13 December 2018
Accepted Date: 14 December 2018
Please cite this article as: I. de la Cueva-Alique, S. Sierra, Adriá. Pérez-Redondo, I. Marzo, L.
Gude, Tomá. Cuenc, E. Royo, Study of the anticancer properties of optically active titanocene
oximato compounds, Journal of Organometallic Chemistry (2019), doi: https://doi.org/10.1016/
j.jorganchem.2018.12.011.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Study of the Anticancer Properties of Optically 1 
Active Titanocene Oximato Compounds  2 
Isabel de la Cueva-Alique,ǂ Sara Sierra,ǂ Adrián Pérez-Redondo,ǂ Isabel Marzo,┴ 3 
Lourdes Gude,ǂ Tomás Cuenca,ǂ Eva Royoǂ* 4 
 5 
Dedicated to the memory of Prof. Dr. Pascual Royo, who loved aquo titanium chemistry 6 
 7 
ǂ  Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación 8 
en Química Andrés del Río (IQAR), Universidad de Alcalá, 28805 Alcalá de Henares, 9 
Madrid, Spain 10 
┴ Departamento de Bioquímica y Biología Molecular y Celular, Universidad de 11 
Zaragoza, 50009 Zaragoza, Spain  12 
Keywords 13 
titanium, chiral, enantiomer, DNA, cytotoxic  14 
Corresponding Author 15 
*E-mail: eva.royo@uah.es. Phone Nr. (+34) 918854629; Fax Nr. (+34) 918854683 16 
ABSTRACT  17 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
New water soluble and optically active cyclopentadienyl titanium derivatives [(η5-1 
C5H5)2Ti{(1R,4S)-ĸON,(R)NH}Cl] (R = Bn (Benzyl) 1a’, 2-pic (2-picolylamine) 1b’) 2 
have been synthesized. The novel compounds along with those previously described 3 
[(η5-C5H5)2Ti{(1S,4R)-ĸON,(R)NH}Cl] (R = Bn 1a, 2-pic 1b) were evaluated by 4 
polarimetry, ultra-violet and circular dichroism spectroscopy. The structure of 1b was 5 
determined by single crystal X-ray crystallography and showed a unique terminal 6 
monohapto Ti-O disposition of the oximato ligand. All enantiomers have been tested 7 
against several cancer cell lines in vitro: prostate PC-3 and DU-145, lung A-549, 8 
pancreas MiaPaca-2, colorectal HCT-116, leukemia Jurkat and cervical HeLa. In 9 
addition, 1a, 1b and 1b’ were tested against non-tumorigenic prostate RWPE-1 cell line. 10 
After 24 h of incubation, 1b and 1b’ were moderately active against Jurkat and A-549 11 
cells. The anti-proliferative effect of titanium compounds on prostate PC-3, DU-145 and 12 
RWPE-1 cell lines was also assessed after 72 h of drug exposure. The cytotoxic profile 13 
of the enantiomers was similar, exception made for the PC-3 cells, with S,R-isomers 14 
exhibiting cytotoxicities 2 to 3 times higher than R,S-compounds. Under these 15 
conditions, derivative 1b showed calculated IC50 values better than those of Tacke´s 16 
Titanocene-Y (bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride) on 17 
both the prostate PC-3 and DU-145 cells. 1a and 1b cytotoxic behaviour shows certain 18 
selectiveness, with activities 2-4 times lower on normal prostate RWPE-1 than on 19 
cancer PC-3 cells. Furthermore, 1b produces higher cytotoxicity on prostate PC-3, DU-20 
145 and RWPE-1 cells than the additive dose of titanocene dichloride and pro-ligand 21 
b·HCl. Additionally, compound-DNA interactions have been investigated by 22 
equilibrium dialysis, Fluorescence Resonance Energy Transfer (FRET) melting assays 23 
and viscometric titrations, which suggest that these metal complexes and/or their 24 
hydrolysis products bind DNA either in the minor groove or externally.  25 
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1. Introduction 1 
Since the successful introduction of cisplatin (cis-[PtCl2(NH3)2]) as an anticancer 2 
drug, much effort has been devoted to investigation of the anticancer activity of other 3 
coordination and/or organometallic transition metal compounds [1-7]. The titanium 4 
derivatives titanocene dichloride ([(η5-C5H5)2TiCl2], TDC) [8,9] and budotitane ([cis-5 
diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV)]) [10,11] were the first metal 6 
compounds to enter clinical trials after platinum complexes. Although these derivatives 7 
showed promising properties in preliminary studies, they failed advanced clinical trials 8 
due to low antitumor efficacy in vivo, rapid hydrolysis and limited solubility in 9 
biological media [12-19]. Since then, a plethora of modified titanium based compounds 10 
have been synthesized and studied as potential antitumor agents [17-29].  11 
The effect of stereochemistry on biological activity is of great importance in medicinal 12 
chemistry, as many of the biological targets are chiral [30,31]. The anticancer properties 13 
of chiral metal derivatives have been largely studied [32-46], but the role of the 14 
stereochemistry in the biological activity of non-platinum based compounds has been 15 
less investigated [22,47-61]. Effect of the absolute configuration on the anticancer 16 
efficiency of titanium compounds was firstly explored by Tshuva in 2010 [50]. The 17 
enantiomers of C2-symmetrical Ti(IV) compounds with chiral diamine bis(phenolato) 18 
ligands showed different antitumor activities by factors of 2-4 on human colorectal  19 
(HT-29) and ovarian (OVCAR-1) carcinoma cells [50,51,56,60]. According to these 20 
results, the authors proposed that stereochemistry should be considered in the design, 21 
modification, and improvement of active compounds [60]. The same year, Baird 22 
published a family of enantiomerically pure titanocene derivatives bearing chiral 23 
alkylammonium groups, but a relationship between the anticancer activity and chirality 24 
could not be established due to the low cytotoxicity showed on the cancer cell lines 25 
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evaluated [62]. Enantiomer-dependent activity was found in chiral substituted 1 
titanocene compounds by Cini et al [22,58], with the (S,S) enantiomer of CpR2TiCl2 2 
(CpR = η5-C5H4CH(CH2CH3)C6H5OMe) being twice as active as the (R,R) isomer 3 
towards pancreatic, breast and colon cancer cell lines, after 24 h of treatment. 4 
Interestingly, lack of enantiomer recognition was observed at 72 h when screening the 5 
compounds in MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 6 
assays.  7 
Within this context, enantiomerically pure, naturally occurring terpenes are useful 8 
building blocks for asymmetric synthesis [63,64]. They are inexpensive and 9 
commercially available reagents in optically pure form, and easily tailored by 10 
stereoselective functionalization [65]. On the other hand, oxime groups are presented as 11 
excellent chemical modifiers, with a wide versatility of coordination modes going from 12 
mono ĸNO, ĸON, to dihapto ĸ2N,O; either with side on or bridging coordination, which 13 
could offer an increased stability of the final compounds when bonded to Ti(IV) acid 14 
centres [66-68]. 15 
We have recently reported a new family of enantiopure cyclopentadienyl titanium(IV) 16 
compounds with amino-oximato ligands derived from R-limonene, of formula [(η5-17 
C5H5)2Ti{(1S,4R)-ĸON,(R)NH}Cl] (R = Bn 1a, 2-pic 1b) (Fig. 1), with relevant 18 
antitumor properties. Our compounds show significant effects on cytotoxicity, cell 19 
adhesion to collagen and migration of androgen-independent prostate cancer cells while 20 
they do not seem to exhibit strong interactions with plasmid DNA by electrophoretic 21 
mobility shift assays. Compounds 1a or 1b suffered hydrolysis in water or phosphate 22 
buffered saline (PBS) solutions. However, the additive doses of TDC and a·HCl or 23 
b·HCl produced lower antiproliferative effects on prostate cancer PC3 cells than those 24 
observed after treatment with oximato titanocenes 1a or 1b, respectively. This fact led 25 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
us to the conclusion that the active operating titanium species was positively influenced 1 
by the presence of the oximato ligand [69].  2 
 3 
Fig. 1 Optically active titanocene compounds containing ligands derived from R-4 
limonene 5 
Encouraged by these previous results, we decided to explore the reactions of TDC 6 
with the already described amino-oxime chiral compounds (1R,4S)-{NH(R),NOH} (R = 7 
Bn a’, 2-pic b’, see Fig. 2) [65,70,71], derived from S-limonene.  8 
 9 
 10 
Fig. 2 Synthesis of optically active titanocene oximato compounds 11 
We report here on the synthesis and characterization of corresponding 12 
cyclopentadienyl Ti(IV) enantiomers [(η5-C5H5)2Ti{(1R,4S)-ĸON,(R)NH}Cl] (R = Bn 13 
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1a’, 2-pic 1b’). Their hydrolytic behaviour has been studied by 1H NMR, Ultraviolet-1 
visible (UV-Vis) spectroscopy and circular dichroism (DC). These novel compounds 2 
along with those previously described have been evaluated against several cancer cell 3 
lines in vitro: prostate PC-3 and DU-145, lung A-549, pancreas MIA PaCa-2, colorectal 4 
HCT-116, leukemia Jurkat and cervical HeLa. In addition, the compounds were tested 5 
against the non-tumorigenic human prostate RWPE-1 cell line. DNA interactions of the 6 
metal derivatives and/or their hydrolysis products have been further investigated by 7 
FRET melting assays, equilibrium dialysis and viscometric titrations experiments.  8 
 9 
2. Experimental Section  10 
2.1. Chemicals and synthesis  11 
Manipulations involving the synthesis of titanium compounds 1a, 1a’, 1b and 1b’ and 12 
Titanocene-Y (bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride) were 13 
performed at an argon/vacuum manifold using standard Schlenk techniques or in a 14 
MBraun MOD System glove-box. Solvents were dried by known procedures and used 15 
freshly distilled. Titanocene-Y [72], (1S,4R)-{NH(R),NOH}, (R = Bn a [70], 2-pic b); 16 
(1R,4S)-{NH(R),NOH} (R = Bn a’; 2-pic b’); corresponding adducts (1S,4R)-17 
{NH(R)·HCl,NOH}, (R = Bn a·HCl, 2-pic b·HCl); (1R,4S)-{NH(R)·HCl,NOH} (R = 18 
Bn a’·HCl, 2-pic b’·HCl) [63,73] and metal compounds [(η5-C5H5)2Ti{(1S,4R)-19 
ĸON,(R)NH}Cl] (R = Bn 1a, 2-pic 1b) [69] were prepared according to previous 20 
reports. R- or S-limonene and isopentyl nitrite were reacted following the standard 21 
method described by Carman et al in 1977 [73]. R-limonene, S-limonene, TDC and 22 
cisplatin were purchased from Sigma-Aldrich. Commercially available reagents were 23 
used without further purification. Nuclear Magnetic Resonance (NMR) spectra were 24 
recorded on a Bruker 400 Ultrashield. 1H and 13C chemical shifts are reported relative to 25 
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tetramethylsilane. 15N chemical shifts are reported relative to liquid ammonia (25 ºC). 1 
Coupling constants J are given in Hertz. Elemental analysis was performed on a LECO 2 
CHNS 932 Analyzer at the Universidad de Alcalá or, alternatively, at the Universidad 3 
Autónoma de Madrid. Fourier Transform Infrared (FT IR) spectra were recorded on IR 4 
FT Perkin Elmer (Spectrum 2000) spectrophotometer on KBr pellets. The pH was 5 
measured in a HANNA HI208 pHmeter in distilled water solutions. Circular Dichroism 6 
(CD) spectra were recorded on a J-715 CD spectropolarimeter (Jasco, UK) at ambient 7 
temperature (297 K). The spectra were determined at a concentration of 0.5 mM in 8 
water using a quartz cuvette of 0.5 cm path length, scan speed of 20 nm·min-1, 0.1 nm 9 
band width, 0.5 nm data pitch and 0.5 s of response time. Optical rotations of all the 10 
compounds solutions were recorded on a Perkin Elmer 341 polarimeter, using the 11 
sodium D line (589 nm) at ambient temperature (297 K) in a quartz cell of 1 dm path 12 
length. Specific optical rotation values were calculated according to the equation [α]24D 13 
= 100·αobs/l·c [74]. Analytical balance and volumetric pipettes (2.0 mL) were used to 14 
prepare CHCl3 solutions of the compounds at concentrations within a range of 7.50-7.80 15 
g·dL-1.  UV-Vis spectra were measured at room temperature on water solutions of the 16 
compounds with a Perkin Elmer Lambda 35 spectrophotometer.  17 
2.1.1. (1R,4S)-{NH(2-pic),NOH} (b’). An analogous procedure to that described 18 
before for the synthesis of b [63] was used, starting from S-limonene [70,71,73]. [α]23D 19 
(deg·dm-1·cm3·g-1) -126 ± 1.3 (b’ at c = 0.7839 g·dL-1, αobs = -0.957 deg); +127 ± 1.3 (b 20 
at c = 0.7604 g·dL-1, αobs = +0.954 deg). All analytical and spectroscopic data are 21 
identical to those observed for b. Anal. Calcd. for C16H23N3O: C, 70.30; H, 8.48; N, 22 
15.37; Found: C, 70.13; H, 8.07; N, 15.20. FT IR (KBr, λmax/cm-1): 3086-3314 (br, 23 
νOH/NH), 1650, 1598 (νC=N). UV-Vis (0.1 mM in H2O:DMSO 99:1): λmax (ε): 261 24 
(316), 340 (10).  1H NMR (plus two dimensional correlation spectroscopy (COSY), 25 
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400.1 MHz, 293 K, chloroform-d1): δ 9.80 (=NOH), 8.49, 7.60, 7.28, 7.11 (m, each 1H, 1 
NC5H4), 4.75 (br, 2H, =CH2), 3.87, 3.61 (both d, each 1H, 3JHH = 6, -CH2-C5H4N), 3.28 2 
(d, 1H, 2JHH = 12, -CH23), 2.60 (br, 1H, NH), 2.09 (m, 1H, -CH4), 2.03 (dd, 1H, 2JHH = 3 
12, 3JHH= 3, -CH23), 2,00, 1.69 (m, each 1H, -CH26 + -CH25), 1.85 (m, 1H, CH26), 1.75 4 
(s, 3H, CH3-C=), 1.65 (m, 1H, CH25), 1.32 (s, 3H, - CH3-Cq-N). 13C NMR (plus 5 
Attached Proton Test (APT), plus gradient Heteronuclear Single Quantum Coherence 6 
(gHSQC), plus Heteronuclear Multiple Bond Correlation (HMBC), 100.6 MHz, 293 K, 7 
chloroform-d1): δ 162.4 (Cq=NOH, Cq is quaternary carbon), 161.1 (Cipso-C5H4N), 8 
148.9 (C=CH2), 149.2, 136.8, 122.7, 122.1 (C5H4N), 109.6 (=CH2), 56.9 (Cq-NH), 48.1 9 
(CH2-C5H4N), 45.0 (CH4), 40.5 (-CH26), 26.4 (-CH25), 25.6 (-CH23), 23.5 (-CH3-CNH), 10 
21.0 (CH3-C=). 15N NMR (gHMBC, 40.5 MHz, 293 K, chloroform-d1): δ 346.7 (C=N-), 11 
305.3 (C5H4N), 51.8 (-NHpic). 12 
2.1.2. [(η5-C5H5)2Ti{(1R,4S)-κON,(Bn)NH}Cl] (1a’). An analogous procedure to that 13 
described for [(η5-C5H5)2Ti{(1S,4R)κON,(Bn)NH}Cl] [69] was followed, starting from 14 
TDC (0.20 g, 0.80 mmol), (1R,4S)-{NH(Bn),NOH} (0.22 g, 0.80 mmol) and NEt3 (0.11 15 
mL, 0.80 mmol). Compound 1a’ was obtained as a yellow-orange solid. Yield: 0.32 g 16 
(88%). [α]23D (deg·dm-1·cm3·g-1) -88.9 ± 1.2 (1a’ at c = 0.7602 g·dL-1, αobs = -0.676 17 
deg), +89.2 ± 1.2 (1a at c = 0.7497 g·dL-1, αobs = +0.681 deg). Analytical and 18 
spectroscopic data of the compound are identical to those already reported [69]. 19 
Solubility in H2O at 24 ºC (mM): 6.6 ± 0.2. Value of pH ([2.0 mM]) in H2O at 24 ºC: 20 
5.54.  Anal. Calcd for C27H33ClN2OTi: C, 66.88; H, 6.86; N, 5.78; Found: C, 66.80; H, 21 
6.90; N, 5.76. FT IR (KBr, λmax/cm-1): 3370 (m, NH), 1646, 1601 (both m, C=N).  1H 22 
NMR (plus HSQC, plus HMBC, plus COSY, 400.1 MHz, 293 K, chloroform-d1): δ 23 
7.32 (m, 5H, -C6H5), 6.39, 6.39 (both s, each 5H, C5H5), 4.76, 4.74 (both s, each 1H, 24 
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=CH2), 3.76, 3.55 (both m, each 1H, -CH2Ph), 2.92 (m, 1H, -CH23), 2.05 (m, 1H, -CH-1 
C=), 1.90 (m, 1H, -CH26), 1.72 (m, 1H, -CH23), 1.68 (m, 1H, -CH25), 1.59 (m, 1H, -2 
CH26), 1.56 (m, 1H, -CH25), 1.25 (br, 1H, NH), 1.47, 1.25 (both s, each 3H, NC-CH3 + 3 
CH3C=). 13C NMR (plus APT, plus gHSQC, plus HMBC, 100.6 MHz, 293 K, 4 
chloroform-d1): δ 159.2 (Cq=N), 149.3 (=Cq-Me), 141.6 (CipsoPh), 128.7, 128.7, 127.2 5 
(C6H5), 117.1, 117.1 (C5H5), 109.4 (=CH2), 57.1 (Cq-NH), 47.3 (-CH2Ph), 45.6 (-CH4), 6 
41.2 (-CH26), 27.8 (-CH23), 26.2 (-CH25), 23.9, 21.3 (CH3-CNH + CH3-C=). 15N NMR 7 
(gHMBC, 40.5 MHz, 293 K, chloroform-d1): δ 398.9 (C=N), 60.0 (NHBn). 8 
2.1.3. [(η5-C5H5)2Ti{(1R,4S)-κON,(2-pic)NH}Cl] (1b’). An analogous procedure to 9 
that described for [(η5-C5H5)2Ti{(1S,4R)-κON,(2-pic)NH}Cl] [69] was followed, 10 
starting from TDC (0.30 g, 1.20 mmol), (1R,4S)-{NH(2-pic),NOH} (0.33 g, 1.20 mmol) 11 
and NEt3 (0.11 mL, 1.20 mmol). Compound 1b’ was obtained as a yellow-orange solid. 12 
Yield: 0.35 g (60%). [α]23D (deg·dm-1·cm3·g-1) -75.7 ± 1.2 (1b’ at c = 0.7534 g·dL-1, 13 
αobs = -0.570 deg), +74.2 ± 1.2 (1b at c = 0.7772 g·dL-1, αobs = +0.570 deg). Solubility 14 
in H2O at 24 ºC (mM): 15.7 ± 1.7. Value of pH ([2.0 mM]) in H2O at 24 ºC: 5.22.  Anal. 15 
Calcd for C26H32ClN3OTi: C, 64.27; H, 6.64; N, 8.65; Found: C, 64.62; H, 7.25; N, 16 
8.54. FT IR (KBr, λmax/cm-1): ῡ 3304 (m, NH), 1640, 1591, 1569 (all s, C=N). 1H 17 
NMR (plus HSQC, plus HMBC, plus COSY, 400.1 MHz, 293 K, chloroform-d1): δ 18 
8.50, 7.60, 7.30, 7.12 (all m, each 1H, -NC5H4), 6.38, 6.38 (both s, each 5H, C5H5), 19 
4.77, 4.74 (both s, each 1H, =CH2), 3.91, 3.70 (both m, each 1H, CH2-C5H4N), 2.84 (m, 20 
1H, -CH23), 2.07 (m, 1H, -CH-C=), 1.98 (m, 2H, overlapped -CH26+3), 1.78 (s, 3H, 21 
CH3C=), 1.64 (m, 1H, -CH26), 1.62 (m, 1H, -CH25), 1.60 (m, 1H, -CH25), 1.48 (br, 4H, 22 
NC-CH3 + NH).  13C NMR (plus APT, plus gHSQC, plus HMBC, 100.6 MHz, 293 K, 23 
chloroform-d1): δ 157.6 (Cq=N), 148.1 (=Cq-Me), 160.2 (CipsoC5H4N), 149.3, 136.7, 24 
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122.9, 122.9 (C5H4N), 117.1, 117.1 (C5H5), 109.6 (=CH2), 48.5 (-CH2-C5H4N), 45.3 (-1 
CH4), 41.1 (-CH26), 27.7 (-CH23), 26.2 (-CH25), 23.9, 21.3 (CH3-CNH + CH3-C=). 15N 2 
NMR (gHMBC, 40.5 MHz, 293 K, chloroform-d1): δ 402.1 (C=N), 312.5 (C5H4N), 52.6 3 
(NHpic). 4 
2.1.5. 1H NMR experiments at physiological pH. Phosphate buffered saline solution 5 
(PBS) was prepared according to Cold Spring Harbor Protocols 6 
(http://cshprotocols.cshlp.org/content/2006/1/pdb.rec8247) using NaCl, KCl, Na2HPO4 7 
and K2HPO4 in D2O. Adjustment of pD (pD = pH* + 0.4, where pH* = pHmeter 8 
reading in D2O) was carried out using a solution of DCl (0.01M) or NaOD (0.01M) in 9 
D2O, with the help of a HANNA HI208 pHmeter. Titanium compounds were then 10 
dissolved in 2000 µL of the freshly prepared PBS, final pD measured (7.30-7.38) and 11 
time-dependent 1H NMR spectra of 500 µL aliquots of final solutions were carried out 12 
at 25 ºC.  13 
2.2. Single-crystal X-ray structure determination  14 
Yellow crystals of pure enantiomer 1b were grown from a hexane-toluene solution. 15 
The crystals were removed from the vial and covered with a layer of a viscous 16 
perfluoropolyether. A suitable crystal was selected with the aid of a microscope, 17 
mounted on a cryo-loop, and placed in the low-temperature nitrogen stream of the 18 
diffractometer. The intensity data sets were collected at 200 K on a Bruker-Nonius 19 
Kappa CCD diffractometer equipped with an Oxford Cryostream 700 unit. The 20 
molybdenum radiation (λ = 0.71073) was used in both cases, graphite 21 
monochromated, and enhanced with an MIRACOL collimator.  22 
The structure was solved, using WINGX package [75], by intrinsic phasing methods 23 
(SHELXT) [76], and refined by least-squares against F2 (SHELXL-2014/7) [77]. 24 
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Crystals of 1b were refined as a two-component inversion twin, and also had two 1 
independent molecules in the asymmetric unit with no significant differences. All non-2 
hydrogen atoms were anisotropically refined. Positions of the amine hydrogen atoms, 3 
H(2) and H(21), were located in the difference Fourier map. H(2) was refined 4 
isotropically, while Uiso for H(21) was fixed with a value of 0.05. The rest of the 5 
hydrogen atoms were positioned and refined by using a riding model. Crystal data for 6 
1b: (C26H32ClN3OTi), FW = 485.89, Monoclinic, space group P21, crystal dimensions 7 
(mm3) 0.30 x 0.27 x 0.27, a = 10.470(1), b = 11.631(1), β = 91.53(1), c = 19.856(3) Å, 8 
V = 2417.2(5) Å3, Z = 4, ρcalcd = 1.335 g cm–3, µ = 0.488 mm–1, F(000) = 1024, θ range 9 
= 3.08 to 27.50 deg, no. of rflns collected = 42638, no. of indep rflns / Rint = 10939 / 10 
0.074, no. of data / restraints / params = 10939 / 1 / 589, R1 / wR2 (I>2σ(I)) = 0.068 / 11 
0.141, R1 / wR2 (all data) = 0.089 / 0.151, GOF (on F2) = 1.167, Absolute structure 12 
parameter = 0.04(5). Final difference Fourier maps did not show peaks higher than 13 
0.695 nor deeper than –0.329 eÅ–3. CCDC-1572920 contains the supplementary 14 
crystallographic data for this paper. These data can be obtained free of charge from The 15 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. 16 
2.3. Cell culture, cytotoxicity assays and cell death analysis 17 
2.3.1. Cell culture 18 
The prostate androgen-unresponsive cancer cell line PC-3 was obtained from the 19 
American Type ulture Collection (Manassas, VA) and may be related to recurrent 20 
prostate cancers that have achieved androgen independence. All culture media were 21 
supplemented with 1% penicillin/streptomycin/amphoterycin B (Life Technologies, 22 
Barcelona, Spain). The culture was performed in a humidified 5% CO2 environment at 23 
37 °C. After the cells reached 70–80% confluence, they were washed with PBS, 24 
detached with 0.25% trypsin/0.2% ethylenediaminetetraacetic acid (EDTA) and seeded 25 
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at 30,000–40,000 cells·cm-2. The culture medium was changed every 3 days. A549 1 
(lung carcinoma) cells were maintained in high glucose DMEM (Dulbecco´s Modified 2 
Eagle´s Medium) and RWPE-1 (non-tumorigenic prostate) cells in DMEM/F12 3 
(Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12), supplemented with 5% 4 
fetal bovine serum (FBS), 200 U·mL-1 penicillin, 100 µg·mL-1 streptomycin and 2 mM 5 
L-glutamine. DU-145 (prostate carcinoma), MIA PaCa-2 (pancreas carcinoma), HCT-6 
116 (colorectal carcinoma), HeLa (cervical cancer) and Jurkat (leukemic cancer) cells 7 
were maintained in RPMI (Roswell Park Memorial Institute) 1640 medium 8 
supplemented with 5% FBS, 200 U·mL-1 penicillin, 100 µg·mL-1 streptomycin and 2 9 
mM L-glutamine. Cultures were maintained in a humidified atmosphere of 95% air:5% 10 
CO2 at 37 °C. Adherent cells were allowed to attach for 24 h prior to addition of 11 
compounds. 12 
2.3.2. MTT Toxicity Assays 13 
For toxicity assays, cells (5 × 104 for Jurkat cells and 104 for adherent cell lines) were 14 
seeded in flat-bottom 96-well plates (100 µL/well) in complete medium. Adherent cells 15 
were allowed to attach for 24 h prior to addition of cisplatin or tested compounds. Stock 16 
solutions of Titanocene-Y, TDC and ammonium-oxime pro-ligands were freshly 17 
prepared in 1% of dimethyl sulfoxide (DMSO) in water, while cisplatin and oximato 18 
titanium compounds were dissolved in culture medium. The stock solutions were then 19 
diluted in complete medium and used for sequential dilutions to desired concentrations. 20 
The final concentration of DMSO in the cell culture medium did not exceed 0.1%. 21 
Control groups with and without DMSO (0.1%) were included in the assays. 22 
Compounds were then added at different concentrations in quadruplicate. Cells were 23 
incubated with compounds for 24 h or 72 h, and then cell proliferation was determined 24 
by a modification of the MTT-reduction method. Briefly, 10 µL/well of [3-(4,5-25 
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) (5 mg·mL-1 in PBS) 1 
was added, and plates were incubated for 1−3 h at 37 °C. Finally, formazan crystals 2 
were dissolved by adding 100 µL/well iPrOH (0.05 M HCl) and gently shaking. The 3 
optical density was measured at 550 nm using a 96-well multi-scanner auto-reader 4 
Enzyme-Linked Inmuno Sorbent Assay (ELISA).  5 
2.4. DNA interaction studies 6 
2.4.1. Equilibrium Dialysis 7 
Duplex DNA from calf thymus (CT DNA), (Deoxyribonucleic acid, Activated, Type 8 
XV) was directly purchased from Sigma Aldrich and used as provided. Duplex-forming 9 
oligonucleotides ds17-1 (5'-CCA GTT CGT AGT AAC CC-3') and ds17-2 (5'-GGG 10 
TTA CTA CGA ACT GG-3') were acquired High Performance Liquid Chromatography 11 
(HPLC) -purified and desalted from Integrated DNA Technologies (IDT). Dialysis 12 
membranes (Spectra/Por® molecular porous membrane tubing MWCO: 3.5–5.0 kDa; 13 
6.4 mm diameter) were purchased from Spectrum Laboratories Inc. Aqueous solutions 14 
of surfactant sodium dodecyl sulphate (SDS) (10%) were purchased from Sigma 15 
Aldrich. The buffer employed in this experiment was 10 mM phosphate buffer 16 
NaH2PO4/Na2HPO4, pH = 7.2, with either 10 mM or 100 mM NaCl. The solutions of 17 
DNA were prepared in the working phosphate buffer at 75 µM monomeric unit (mum.) 18 
concentrations, in base pairs. For the preparation of the short oligonucleotide solution, 19 
an annealing step was needed, with heating at 90 °C for 10 min and then gradually 20 
cooling to 25 °C during 3 h. The solutions were left at 4 °C overnight.  21 
Dialysis bags, previously washed with milli-Q water, were filled with 75 µM (m.u.) 22 
of DNA duplex (200 µL each bag) and placed in a beaker containing 225 mL of ca. 2 23 
µM solution of the tested compound. The beaker was covered with parafilm and 24 
aluminium foil and allowed to equilibrate during 24 h at room temperature. Experiments 25 
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were run, at least, in triplicate. Once the dialysis process had been completed, the 1 
solutions from each dialysis bag were transferred to Eppendorf tubes. The content of 2 
each bag was then mixed with an aqueous detergent solution (10%) to reach a 1% 3 
concentration (v/v) of SDS. The concentrations of free compound in the dialysate 4 
solution and compound in the dialysis bags were determined by absorbance 5 
measurements using the extinction coefficients of the metal complexes (determined in 6 
the presence and absence of the detergent) and apparent association constants were 7 
calculated [78]. 8 
2.4.2. DNA FRET melting assay 9 
The DNA melting assay was performed on a quantitative PCR kit ABI PRISM® 7000 10 
Sequence Detection System (Applied Biosystems) in a 96-well plate format (96-Well 11 
Optical MicroAmp® Reaction Plate, Applied Biosystems, Life Technologies 12 
Corporation). The oligonucleotide sequence employed in this experiment, F10T (5'-13 
FAM-AGC TAT TA /sp18/ TA TA GCT ATA-TAMRA-3') was produced, HPLC-14 
purified and desalted by IDT. FAM is 6-carboxyfluorescein and TAMRA is 15 
carboxytetramethylrhodamine. The buffer system used in this experiment was: 10 mM 16 
sodium cacodylate, 100 mM LiCl, (pH = 7.3). First, the duplex-forming oligonucleotide 17 
was dissolved in water (grade BPC) and a 50 µM stock solution was prepared, which 18 
was then diluted to 0.5 µM.  Then, the diluted DNA solution was mixed with the 19 
working buffer (2x) and water Biotechnology Performance Certified (BPC) grade. The 20 
DNA solution was heated at 90 °C for 10 min, cooled down slowly for 3 h and left at 21 
4 ºC overnight. Compounds to be tested were dissolved in water and approximately 1 22 
mM stock solutions were prepared. The exact concentrations were checked by UV-Vis. 23 
Stock solutions were then diluted with buffer to obtain 50 µM solutions of each 24 
compound. In a 96-well microplate, DNA solutions were mixed with solutions of tested 25 
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compound and buffer to reach a total volume of 50 µL with a F10T concentration of 0.2 1 
µM and a compound concentration ranging between 1 and 10 µM.  2 
The experimental protocol consisted of an incubation for 5 min at 24 °C, followed by 3 
a temperature ramp with heating rate 1 °C/min. Fluorescence values corresponding to 4 
the fluorophore FAM at wavelength of 516 nm (after excitation at 492 nm) were 5 
collected at each degree of temperature. Afterwards, the fluorescence data were 6 
normalized, plotted against temperature (ºC) at each compound concentration, and Tm 7 
values were determined. 8 
2.4.3. Viscometric titrations 9 
Duplex DNA from CT (Deoxyribonucleic acid, Activated, Type XV) was purchased 10 
from Sigma Aldrich and used as provided. The buffer employed in this experiment was 11 
10 mM phosphate buffer NaH2PO4/Na2HPO4, pH = 7.2. The viscosity measurements 12 
were performed in a Visco System AVS 470 at 25.00 ± 0.01 ºC, using a 13 
microUbbelohde (K = 0.01) capillary viscometer. 6 mL of DNA solution (0.4 mM in 14 
nucleotides) in phosphate buffer were equilibrated for 20 min at 25.00 ºC and then 20 15 
flow times were registered. Small aliquots (30–50 µL) of solutions of metal complexes 16 
(1.6–2.3 mM) were added to the same DNA solution. Before each flow time 17 
registration, the solutions were equilibrated for 20 min to 25.00 ºC and then 20 flow 18 
times were measured. With the averaged time of the different flow time measurements 19 
and the viscometer constant, the viscosities (µ) for each point were calculated. The 20 
viscosity results were plotted as (µ/µ0)1/3, where µ0 represents the DNA solution 21 
viscosity in the absence of the ligand, versus (r), representing the ratio [ligand]/[DNA].   22 
2.5. Data analysis 23 
Results were subjected to computer-assisted statistical analysis using One-Way 24 
Analysis of Variance ANOVA, Bonferroni´s post-test, and Student´s t-test. Data are 25 
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shown as the means of individual experiments and presented as the mean ± SD 1 
(Standard deviation). Differences of P < 0.05 were considered to be significantly 2 
different from the controls. 3 
3. Results and Discussion 4 
3.1. Synthesis and characterization of metal compounds 5 
Synthesis of the novel Ti(IV) compounds was carried out analogously to that of 6 
previously described enantiomers 1a and 1b [69]. Treatment of TDC and amino-oxime 7 
derivatives a’ or b’ in the presence of NEt3 allows isolation of novel chiral-at-ligand 8 
titanium compounds 1a’ or 1b’, respectively (Fig. 2), which are formed together with 9 
Et3N·HCl.  10 
Analytical and spectroscopic data of the novel compounds 1a’ and 1b’ are identical to 11 
those reported before for 1a and 1b, respectively (see ref [69], Experimental Section 12 
and Online Resource, Fig. S3-S9).  13 
Calculated data of specific optical rotation in chloroform solution for the ligands and 14 
novel metal derivatives ([α]23D (deg·dm-1·dL·g-1) = -127 ± 1.3 a’, +130 ± 1.3 a, -126 ± 15 
1.3 b’, +127 ± 1.3 b, -88.9 ± 1.2 1a’, +89.2 ± 1.2 1a, -75.7 ± 1.2 1b’, +74.2 ± 1.2 1b) 16 
evidence the enantiomeric relationship of the stereoisomers. Furthermore, absolute 17 
configuration of the compound 1b has been confirmed through X-ray structure 18 
determination (Fig. 3, and Online Resource Table S1, S2 and Fig. S16).  19 
 20 
 21 
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 1 
Fig. 3 ORTEP drawing of compound 1b with 50% probability ellipsoids. Hydrogen 2 
bonded to carbon atoms have been omitted for clarity. Representative bond lengths (Å) 3 
and angles (deg): Ti(1)-Ct(1) 2.073; Ti(1)-Ct(2) 2.065; Ti(1)-Cl(1) 2.380(2); Ti(1)-O(1) 4 
1.899(4); Ti(1)·· ·N(1) 2.866(5); N(1)-O(1) 1.403(6); N(1)-C(21) 1.273(8); Cl(1)-Ti(1)-5 
O(1) 92.4(2); Ti(1)-O(1)-N(1) 119.6(3); O(1)-N(1)-C(21) 114.1(5); Ct(1)-Ti(1)-Ct(2) 6 
130.3; (Ct(1) is the centroid of the C(11)-C(15) ring, Ct(2) is the centroid of the C(16)-7 
C(20) ring) 8 
 9 
The X-ray crystal structure determination of 1b shows the presence of two 10 
independent molecules in the asymmetric unit, with the same absolute configuration of 11 
the two chiral centers; an ORTEP diagram of one of them is presented in Fig. 3. The 12 
crystallographic study confirms a monohapto coordination of the oximato unit to the 13 
titanium atom. The compound shows a pseudotetrahedral environment around the metal 14 
centre, with Ti-O bond distances and O-N-C angles slightly shorter and closer (Online 15 
Resource Fig. S16), respectively, than those found in analogous biscyclopentadienyl 16 
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oximato titanium(IV) derivatives [66,68] or alcoxo oximato titanium(IV) compounds 1 
[79-82] with a dihapto κ2NO coordination of the oximato unit to the titanium centre.  2 
To the best of our knowledge, this is the first example found of an oximato titanium 3 
derivative with a terminal monohapto Ti-ON= coordination, where this coordination 4 
mode is probably caused by the large steric requirements of the functionalized 5 
cyclohexane residue. This terminal coordination may account for the hydrolysis 6 
suffered for the compounds in aqueous media. In contrast, dihapto titanocene oximato 7 
compounds [(η5-C5H5)2Ti(H2O)(κ2O=NR)]+ (R = CMe2; C6H10), reported by Thewalt et 8 
al [66], were described as surprisingly stable against air and water.  9 
The reactions in water or PBS solutions of 1a or 1b were elucidated in a previous report 10 
and afford soluble ammonium-oxime pro-ligands (1S,4R)-{NH(R)·HCl,NOH} (R = Bn 11 
a·HCl or 2-pic b·HCl, respectively), together with aqua-oxo or –hydroxo 12 
biscyclopentadienyltitanium(IV) species [69,83,84] which are detected at least during 13 
the first three hours after dilution. The same behavior as that described before has now 14 
been observed for novel compounds 1a’ and 1b’ when their solutions in water-d2 or 15 
PBS were studied by 1H NMR spectroscopy (see Online Resource, Fig. S10).  16 
We decided to further investigate the existence of an amino-oxime ligand containing 17 
Ti(IV) species, which could account for the observed stereoisomer-dependent cytotoxic 18 
behaviour of the compounds on the prostate cancer PC-3 cell line.  Since UV-Vis 19 
spectroscopy is considered a more sensitive technique than NMR, we recorded time-20 
dependent UV-Vis spectra for compounds 1a’ and 1b’ in PBS solution. Right after 21 
dilution, UV-Vis spectrum of 1a’ (Online Resource Fig. S13) and 1b’ (Fig. 4) shows 22 
two very broad absorption bands centered at 240 and 325, and 246 and 322 nm, 23 
respectively, ascribed to overlapping of LMCT bands due to cyclopentadienyltitanium 24 
aquo cations and the absorption bands corresponding to proligands a’·HCl and b’·HCl. 25 
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After 24 h, only the absorption bands assigned to a’·HCl or b’·HCl, at 250 and 332, 1 
and 260 and 332 nm, respectively, are detected. Similar UV-Vis spectra are obtained 2 
after 72 h. Analogous results were obtained when the compounds are diluted in pure 3 
water.  4 
 5 
Fig. 4 Comparison of time-dependent UV-Vis spectra of 1b’ with b’·HCl and TDC 6 
spectra in PBS solution 7 
CD spectra were also recorded for each pair of enantiomers. However, the spectra of 8 
derivatives 1a, 1b and 1a’, 1b’ are identical to those obtained for ammonium-oxime 9 
compounds a·HCl, b·HCl, a’·HCl, b’·HCl (see Online Resource Fig. S14, S15), 15 10 
min after dilution or after 72 h, leading to the assumption that those are the only 11 
detectable optically active, soluble in water products of the hydrolysis of titanium 12 
oximato compounds.  13 
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3.2. In vitro cell studies  1 
 3.2.1. Anti-proliferative studies 2 
Chiral compounds 1a and 1b have already shown their promising anticancer 3 
properties on the human prostate and renal cancer cell lines PC-3 and Caki-1.  Both 4 
titanocenes, especially 1b, are considerable less toxic to the non-tumorigenic human 5 
embryonic kidney cell line HEK-293T than to Caki-1 renal cells (7-15-fold less toxic) 6 
[69].  7 
In order to compare and evaluate the versatility of the different enantiomers, the 8 
cytotoxic activity of pro-ligands a·HCl, a’·HCl, b·HCl, b’·HCl and metal compounds 9 
TDC, Tacke´s Titanocene-Y [72,85,86], 1a, 1a’, 1b and 1b’ was now assessed after 24 10 
h of incubation time on a wide variety of human cancer cell lines, i.e. prostate PC-3 and 11 
DU-145, lung A-549, pancreas MIA PaCa-2, colorectal HCT-116, leukemia Jurkat and 12 
cervical HeLa. The in vitro effect of the compounds on cytotoxicity was firstly 13 
evaluated by monitoring their ability to inhibit cell growth using the MTT assay.  14 
Under these conditions, pro-ligands a·HCl, a’·HCl, b·HCl, b’·HCl and metal 15 
compounds 1a and 1a’, TDC, and Titanocene-Y are poorly cytotoxic in all tested cell 16 
lines (IC50 > 150 µM under these experimental conditions). Enantiomers 1b and 1b’ are 17 
also not effective, after 24 h of exposure, in prostate PC-3, pancreatic MIA PaCa-2 or 18 
colon HCT-116 human carcinoma cell lines, but show inhibitory activities of 40-50% 19 
and 20-25% at concentrations of 50 µM against human lung carcinoma A-549 (Online 20 
Resource Fig. S17) and leukemia Jurkat-T cell lines respectively. Cell morphology 21 
evaluation of A-549 cells indicated that titanium derivatives 1b and 1b’ did not induced 22 
apoptotic cell death, since no apoptotic cells, characterized by condensed nuclei and 23 
membrane blebbing, were detected. Cisplatin was included in the experiment as a 24 
positive control of apoptosis. 25 
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Since compounds 1a and 1b had shown to be efficiently cytotoxic on the PC-3 cell 1 
line after 72 h of incubation with the cells [69], we decided to assess the anti-2 
proliferative effect of titanium compounds on prostate PC-3 and DU-145 cell lines as 3 
the IC50 value after 72 h of drug exposure. The results are summarized in Table 1.  4 
Table 1. IC50 values (µM) of cisplatin, Titanocene-Y and enantiomers 1a, 1a’, 1b and 5 
1b’ in prostate cancer PC-3, DU-145 and non-tumorigenic RWPE-1 cell lines,a (n.m. 6 
not measured) 7 
Compound PC-3 DU-145 RWPE-1 
1a > 150 (24 h)                        
48.7 ± 3.2 (72 h) > 150 (72 h)                        
 
> 200 (72 h) 
1a’  > 150 (24 h) 
> 150 (72 h) 
 
> 150 (72 h)                        n.m. 
1b > 150 (24 h) 
14.5 ± 3.1 (72 h) 
 
27.1 ± 1.1 (72 h) 
 
30.8 ± 0.57 (72 h) 
1b’ > 150 (24 h) 
49.9 ± 7.0 (72 h) 
 
23.9 ± 8.6 (72 h) 
 
43.8 ± 7.2 (72 h) 
1b + 1b’  
37.5 ± 5.1 (72 h) n.m. n.m. 
Titanocene-Y > 200 (24 h) 
58.1 ± 11.2 (72 h) 
 
> 150 (72 h) 
 
42.9 ± 0.73 (72 h) 
cisplatin 104.2 ± 8.1 (24 h) 
14.5 ± 2.5 (72 h) 
 
3.7 ± 0.6 (72 h) 
 
19.9 ± 1.1 (72 h) 
a
 Each value represents the mean ± S.D. (n = 3)      8 
 9 
Under these conditions, the enantiomer 1b shows IC50 values on the prostate PC-3 10 
and DU-145 cell lines 2-5 times lower than Tacke´s compound, Titanocene-Y. The 11 
cytotoxicity on PC-3 cells of the titanium enantiomers 1a and 1b, with the absolute 12 
configuration S,R-, is higher than that of the R,S-stereoisomers by a factor of ca. 2-3, 13 
while the racemic mixture of 1b and 1b’ afford IC50 values average between the two 14 
enantiomers. In contrast, no enantiomer recognition is observed on the prostate DU-145 15 
cells for derivatives 1b, 1b’, while 1a, 1a’ resulted not to be efficient in this non-16 
hormone dependent cancer cell line.  17 
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Titanocene-Y has already shown an encouraging activity in PC-3 tumour-bearing 1 
mice [85]. Other titanium compounds which have proved their in vitro antitumor 2 
activity in prostate cancer cell lines under similar time exposure conditions are Schiff-3 
base titanium (IV) derivatives [87] (IC50 values within the range 5-18 µM, in PC-3) or 4 
heterometallic titanocene-gold compounds (IC50 values ranged from 27-40 µM in PC-3 5 
[88,89], and 11.8-27.6 µM in DU-145 [24,90].   6 
In order to analyse the cytotoxic selectiveness to healthy cells, the isomers 1a, 1b and 7 
1b’ were also tested in the non-tumorigenic human prostate (RWPE-1) cells. Regarding 8 
selectivity, 1a and 1b are less toxic to the non-tumorigenic RWPE-1 than to the cancer 9 
PC-3 cells (from 2 to 4 times less toxic), while 1b’ shows a similar behaviour relative to 10 
the cancer DU-145 cells.  11 
Titanium compound 1b was selected for a further study in vitro. We evaluated a 12 
combination of TDC and pro-ligand b·HCl on the cellular viability after 72 h of 13 
exposure to the drug. As already described in the PC-3 cell line,[69] the additive dose of 14 
both starting materials also produced lower anti-proliferative effects than those observed 15 
after treatment with only 1b (Table 2) in the prostate DU-145 and RWPE-1 cell lines. 16 
These results are consistent with the involvement of metal oxime containing species in 17 
the cytotoxicity mechanism. While water soluble hydrolysis species detected in our 18 
studies are the same as those formed from a mixture of TDC and amino-oxime 19 
proligand, the existence of polinuclear, ligand influenced species formed in a colloidal 20 
phase of hydrolysis cannot be ruled out. 21 
 22 
 23 
 24 
 25 
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Table 2. Comparison of IC50 values (µM) of 1b, b·HCl, TDC and TDC+b·HCl in 1 
prostate cancer PC-3, DU-145 and non-tumorigenic RWPE-1 cell linesa (after 72 h of 2 
exposure to the drug). 3 
Compound PC-3 DU-145 RWPE-1 
1b 14.5 ± 3.1 27.1 ± 1.1 30.8 ± 0.57 
b·HCl 
> 100 106.1 ± 10.4 140.5 ± 23.0 
TDC+b·HCl 39.5 ± 2.1 54.9 ± 13.5 > 150 
TDC 
> 150 > 150 > 150 
a
 Each value represents the mean ± S.D. (n = 3) 4 
 5 
 3.3. DNA binding  6 
To date, various distinct mechanisms have been proposed for titanium-based 7 
therapeutics. DNA binding is still thought to be one important potential mode of action 8 
for titanocene compounds, although interactions with DNA have been found to be 9 
generally very weak at physiological pH conditions [16,17]. The study of DNA 10 
interactions for these particular metal complexes does often represent an experimental 11 
challenge, since the compounds can easily hydrolyse in water solutions. That said, 12 
investigation in this area may be used to shed some light about the nature of the 13 
interactions that may partially account for the biological activity observed in 14 
physiologically relevant aqueous environments, albeit the results obtained should be 15 
interpreted cautiously. Our previous results showed that titanocenes 1a or 1b did not 16 
exhibit strong interactions with plasmid DNA by electrophoretic mobility shift assays, 17 
but the absence of a shift in the electrophoretic bands did not allow us to rule out DNA 18 
binding. Having established the interesting antitumor properties of metal compounds 19 
1a, 1a’, 1b and 1b’, our aim with the study presented now was to further analyse and 20 
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compare the kind of potential interactions of the enantiomers with DNA, by using other 1 
techniques to complement previous studies.  2 
Dialysis experiments, based on the fundamental thermodynamic principle of 3 
equilibrium dialysis [78,91], were performed to determine apparent binding constants 4 
between DNA and the metal compounds, following the protocol described by Chaires 5 
[78] with some modifications. As the DNA targets, we selected CT DNA and a short 6 
oligonucleotide duplex of known sequence (ds17, 17 bp).  7 
Unfortunately, under the conditions employed, large dispersion data sets were 8 
obtained, which prevented the precise determination of association constants between 9 
the titanium(IV) compounds and DNA. This is likely to be a consequence of the 10 
hydrolysis of these complexes in aqueous media. However, even if the results should be 11 
interpreted with caution, a significant increase in compound concentration was 12 
invariably observed in the dialysis bags of replicate experiments, suggesting effective 13 
DNA binding by metal complexes 1a, 1a’, 1b, 1b’ and/or their hydrolysis products. 14 
With the purpose of determining the effect that these compounds may exert on the 15 
DNA denaturing temperature, Tm, we used a variable-temperature (FRET-melting) 16 
assay. This experiment requires little DNA consumption, allows the assessment of a 17 
wide range of compound concentrations, can be adapted to a high-throughput fashion, 18 
and it has been extensively used to determine the degree of thermal stabilization of 19 
different DNA structures in the presence of potential ligands [92]. Thus, FRET 20 
experiments were used to establish whether metal complexes 1a, 1a’, 1b and 1b’ were 21 
able to thermally stabilize duplex DNA structures.  22 
In these experiments, a 10-bp oligonucleotide (F10T) labelled with two fluorophores, 23 
FAM at its 5' end and TAMRA at the 3' end, was selected [93]. If the metal complex 24 
binds to DNA affecting the stability of the helix, changes in the value of DNA Tm 25 
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should be expected. Stabilization of duplex DNA usually results in increased values of 1 
Tm.  2 
Compounds 1a, 1a’, 1b and 1b’ were analysed for their ability to affect duplex DNA 3 
melting within the 1-10 µM concentration range. However, under these conditions, the 4 
titanium(IV) derivatives were not able to produce a significant change in the DNA 5 
melting temperature. Furthermore, none of the enantiomers of the precursor ligand, 6 
a·HCl, a’·HCl, showed DNA stabilization (see Online Resource Fig. S18). These 7 
results suggest that the compounds may interact with DNA in an external, mainly 8 
electrostatic fashion or through partial recognition of the DNA grooves.   9 
Finally, DNA viscometric titrations were carried out because viscosity measurements 10 
can provide a simple way to discriminate between the different binding modes of 11 
potential DNA ligands (such as intercalation versus groove or external binding) [94]. 12 
According to the theory of Cohen and Eisenberg [95], from gradual titration of DNA 13 
solutions with the compounds of interest, linear plots of the cubed root of the relative 14 
DNA viscosity (η/ηo)1/3 versus the molar ratio of bound ligand to DNA nucleotide (r) 15 
can be obtained. The slope values in these plots correlate well with the DNA-ligand 16 
binding modes. Groove binding compounds normally display a slope close to 0.0, 17 
whereas classical mono-intercalants result in a slope close to 1.0 [94,95].  18 
The tested compounds showed a linear (η/ηο)1/3 versus r correlation in the typical r 19 
range used in these experiments (Fig. 5). Complexes 1a, 1a’, 1b and 1b’, irrespective of 20 
the amino-bound ligand and the stereochemistry of the metal complex, gave rise to 21 
slope values practically equal to zero. 22 
 23 
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 1 
Fig. 5 Viscometric titrations of CT DNA and metal complexes 1a, 1a’, 1b and 1b’ at 25 2 
ºC (10 mM sodium phosphate buffer, pH 7.2) 3 
 4 
These results are in good agreement with the FRET DNA melting assays and point 5 
towards an external or groove interaction of the titanium metal complexes and/or their 6 
hydrolysis products that does not result in overall changes of contour length or thermal 7 
stabilization of the DNA double helix structure.  8 
 9 
4. Conclusions 10 
Optically active amino-oxime ligands derived from natural products are useful and 11 
inexpensive starting materials for the design of enantiopure titanocene compounds. In 12 
contrast with the resistance to hydrolysis of other ĸ2N,O oximato-Ti biscyclopentadiene 13 
compounds described before, our systems suffer hydrolysis in water at physiological 14 
conditions, most likely due to the monohapto ĸON coordination mode of the highly 15 
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sterically demanding limonene residue of the oximato ligand. Regarding their cytotoxic 1 
behaviour, the oxime-containing Ti(IV) compound 1b has shown potent anticancer 2 
activities against both prostate cancer PC-3 and DU-145 cell lines after 72 h of 3 
incubation time. The cytotoxicity of the enantiomers 1a, 1a’ and 1b’, 1b’ towards all 4 
the cancer cell lines tested showed no significant differences, exception made for the 5 
PC-3 cells. In addition, isomers 1a and 1b showed certain selectivity in their toxicity 6 
against prostate cancer PC-3 versus non-tumorigenic RWPE-1 cells. Furthermore, 7 
compound 1b shows higher activity than the additive dose of TDC and proligand b·HCl 8 
on the prostate PC-3, DU-145 and RWPE-1 cell lines. These results point towards the 9 
existence of an influence of the oximato-Ti unit on the hydrolysis process and/or the 10 
cytotoxicity mechanism. Compound-DNA interactions have been investigated by 11 
equilibrium dialysis, FRET melting assays and viscometric titrations. The experimental 12 
results suggest that these metal complexes and/or their hydrolysis products can bind 13 
DNA either in the minor groove or externally, irrespective of the ligand 14 
stereochemistry.  15 
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Highlights (85 characters)  
• Synthesis of novel enantiopure titanocene amino-oximato compounds is 
reported.  
• The X-ray crystal structure of one of the compounds shows a unique monohapto 
Ti-ON coordination. 
• One enantiomer shows IC50 values lower than Titanocene-Y on both PC-3 and 
DU-145 cells. 
• One enantiomer is more active than additive doses of Ti(η5-C5H5)Cl2 and oxime 
pro-ligand. 
